Who Benefits Most from THC:CBD Spray? Learning from Clinical Experience

Publisher： Karger

E-ISSN： 1421-9913|71|1|10-15

ISSN： 0014-3022

Source： European Neurology, Vol.71, Iss.1, 2014-01, pp. : 10-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

THC:CBD Spray and MS Spasticity Symptoms: Data from Latest Studies

By  

European Neurology, Vol. 71, Iss. 1, 2014-01 ,pp. : 4-9

Karger

Access to resources Recommend Favorite

Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study

By  

European Neurology, Vol. 74, Iss. 3-4, 2015-11 ,pp. : 178-185

Karger

Access to resources Recommend Favorite

THC:CBD in Daily Practice: Available Data from UK, Germany and Spain

By  

European Neurology, Vol. 75, Iss. 1, 2016-0 ,pp. : 1-3

Karger

Access to resources Recommend Favorite

Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity

By  

European Neurology, Vol. 71, Iss. 5-6, 2014-02 ,pp. : 271-279

Karger

Access to resources Recommend Favorite

Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity

By  

European Neurology, Vol. 75, Iss. 5-6, 2016-05 ,pp. : 236-243

Karger

Access to resources Recommend Favorite